Patients with a combined immunodeficiency characterized by normal numbers but impaired function of T and B cells had a homozygous p.Tyr20His substitution in transferrin receptor 1 (TfR1), encoded by TFRC. The substitution disrupts the TfR1 internalization motif, resulting in defective receptor endocytosis and markedly increased TfR1 expression on the cell surface. Iron citrate rescued the lymphocyte defects, and expression of wild-type but not mutant TfR1 rescued impaired transferrin uptake in patient-derived fibroblasts. Tfrc Y20H/Y20H mice recapitulated the immunological defects of patients. Despite the critical role of TfR1 in erythrocyte development and function, patients had only mild anemia and only slightly increased TfR1 expression in erythroid precursors. We show that STEAP3, a metalloreductase expressed in erythroblasts, associates with TfR1 and partially rescues transferrin uptake in patient-derived fibroblasts, suggesting that STEAP3 may provide an accessory TfR1 endocytosis signal that spares patients from severe anemia. These findings demonstrate the importance of TfR1 in adaptive immunity.
Combined immunodeficiencies (CID) are characterized by lifethreatening infections due to genetic defects resulting in impaired T-and B-lymphocyte development or function 1 . The 41 documented monogenic causes of CID have identified pathways and molecules important for adaptive immunity, but many patients with CID remain without a genetic diagnosis 1 . We report the first human immunodeficiency caused by defective iron transport. Fig. 1 ) had severe childhood infections, leading to the death of six individuals (Supplementary Table 1 ). Three patients (A1, A2 and A3) followed at our center had hypogammaglobulinemia, normal lymphocyte counts, intermittent neutropenia and intermittent thrombocytopenia (Supplementary Tables 2 and 3) . Hematological parameters were normal, except for borderline-low hemoglobin levels in two patients and low mean corpuscular volume (MCV) in all three (Supplementary Table 2 ). Data on six additional patients showed severe hypogammaglobulinemia and mild anemia resistant to iron supplementation (data not shown). Eight patients received early hematopoietic stem cell transplantation (HSCT) from matched siblings, with resolution of clinical and laboratory abnormalities.
Fourteen Kuwaiti children in family A (Supplementary
Patient 1 of family B from western Saudi Arabia is the 5-year-old son of consanguineous parents, with early-onset chronic diarrhea and recurrent infections (Supplementary Table 1 ). He had agammaglobulinemia, normal lymphocyte counts, intermittent thrombocytopenia, mildly low hemoglobin levels and low MCV (Supplementary Tables 2  and 3) . He was treated with antibody against CD20 for presumed autoimmune thrombocytopenia, resulting in loss of circulating B cells without clinical improvement.
The numbers of circulating total (CD3 + ), helper (CD4 + ) and cytotoxic (CD8 + ) T cells, natural killer (NK; CD3 − CD16 + /CD56 + ) cells and B (CD19 + ) cells in patients were normal or nearly normal. However, percentages of CD19 + CD27 + memory B cells, important for antibody production, were reduced among CD19 + B cells (Supplementary Table 3 ).
Proliferation of peripheral blood mononuclear cells (PBMCs) in
A missense mutation in TFRC, encoding transferrin receptor 1, causes combined immunodeficiency response to the mitogen phytohemagglutinin (PHA), cross-linking of the T cell receptor (TCR) with antibody against CD3, and combined phorbol 12-myristate 13-acetate (PMA) and ionomycin, which bypasses the TCR, was significantly decreased for cells from all four patients (Fig. 1a) . T cell co-stimulation using antibody against CD28 or addition of interleukin (IL)-2 growth factor did not correct the defective TCR-driven proliferation, which was not associated with increased incidence of apoptosis (data not shown). These observations demonstrate a global defect in T cell proliferation.
Ligation of CD40 on B cells by CD40 ligand expressed on activated T cells in the presence of IL-4 causes proliferation-dependent immunoglobulin class-switch recombination from IgM to IgG and IgE, reflective of the production of high-affinity, protective antibodies 2 . Proliferation and secretion of IgG and IgE in response to combined exposure to antibody against CD40 and IL-4 were significantly decreased in patient-derived PBMCs in comparison to control cells (Fig. 1b) . IgE switching requires expression of Iε-Cε germline transcripts, which are early products of class-switch recombination, and activation-induced cytidine deaminase (AICDA), which initiates deletional switch recombination followed by expression of mature Iµ-Cε transcripts 3 . The patients had normal expression of immature Iε-Cε germline transcripts and AICDA mRNA in their B cells, but mature Iµ-Cε transcripts were undetectable (Fig. 1c) . Collectively, these data demonstrate impaired T cell proliferation as well as defective B cell proliferation and class-switching, which in combination constitute the mechanism underlying the susceptibility to severe infections characteristic of CID 1 .
Genome-wide linkage scans of family A implicated a single locus at chromosome 3q28-29, but no pathogenic mutation was found within Figure 1 Lymphocyte dysfunction in patients A1-A3 and B1. (a) PBMC proliferation in response to PHA, antibody against CD3 (α-CD3), combined PMA and ionomycin (PMA + IO), and tetanus toxoid antigen (TT). There were insufficient cells from patient B1 for proliferation studies involving tetanus toxoid antigen. (b) B cell proliferation and IgG and IgE production in response to combined stimulation with antibody against CD40 (α-CD40) and IL-4. Patient B1 was not studied in these assays because of his lack of circulating B cells. In a and b, symbols represent individual patients (Pt) and controls (C). Graphs display means ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001. (c) Molecular events in IgE switching as shown by PCR of B cell cDNA. GLT, germline transcript; AICDA, activation-induced cytidine deaminase; GAPDH, glyceraldehyde 3-phosphate dehydrogenase, used as a housekeeping gene control. (g,h) Immunofluorescence analysis of uptake of Alexa Fluor 568-labeled transferrin 30 min after transferrin addition by serum-starved fibroblasts (n = 3 per group) (g) and transduced patient-derived fibroblasts (n = 3 patients) (h). WT, wild type. Scale bars, 10 µm. The graphs in g and h show the pooled results from three patients (A1-A3). Results represent net MFI after background subtraction. Graphs in f-h display means ± s.e.m. *P < 0.05, **P < 0.01, ***P < 0.001. l e t t e r s npg l e t t e r s this linkage peak (Supplementary Note). Therefore, whole-genome sequencing was performed on patient A1, his unaffected father and patient A2. A missense mutation in TFRC (c.58T>C; NM_003234.2), which encodes transferrin receptor 1 (TfR1; also known as CD71), was the only rare nonsynonymous or splice-site mutation homozygous in both patients and heterozygous in the obligate carrier father (Fig. 2a) . TFRC is located 919 kb downstream of the distal boundary of the linkage peak; this unexpected location can be explained by recent de novo occurrence of the mutation and segregation of both the mutant and non-mutant copies of the disease-associated haplotype within the family (Supplementary Note). The c.58T>C mutation segregated perfectly with the disease phenotype in 34 available family members and was absent from multiple variant databases and 731 genotyped controls (Supplementary Table 4 ). The resulting p.Tyr20His substitution (NP_003225.2) disrupts the TfR1 intracellular internalization motif 4 ( Fig. 2b) , and the Tyr20 residue is perfectly conserved in the 81 non-human vertebrate species surveyed ( Supplementary Fig. 2 ). Because of the similarities among patients from families A and B, we performed Sanger sequencing for the c.58T>C mutation in family B; the mutation was homozygous in patient B1 and heterozygous in his parents and his sister (Fig. 2a) . Although the families were from different geographic regions and not known to be related, patient B1 shares a homozygous haplotype with the five genotyped patients from family A across a 3.3-Mb interval at chromosome 3q29-ter that , and molecular events in IgE isotype switching (c). In graphs, bars represent means ± s.e.m. from three independent experiments; *P < 0.05, ***P < 0.001. Results for all graphs represent means ± s.e.m.; *P < 0.05, **P < 0.01, ***P < 0.001. npg l e t t e r s includes TFRC, suggesting identical-by-descent inheritance of the mutation from an unknown common ancestor.
TfR1 is important for cellular iron uptake. Circulating apotransferrin binds two Fe 3+ ions to form holotransferrin, which binds to TfR1 (ref. 5). The TfR1-holotransferrin complex is internalized by receptor-mediated endocytosis, which requires an aromatic residue at the Tyr20 position mutated in the patients 6 . When intracellular iron levels are low, iron-regulatory proteins bind to the 3′ UTR of TFRC mRNA, increasing its stability 7 . TFRC mRNA and TfR1 protein levels were higher in PBMCs from patients than in controls (Fig. 2c,d) , consistent with this feedback mechanism. TfR1 was minimally expressed on the cell surface of unstimulated control T and B cells but was expressed on a large percentage of patient-derived T and B cells, at levels 13-and sevenfold higher, respectively, than on controls (Fig. 2e) . Likewise, TfR1 expression was sixfold higher on the cell surface of patient-derived fibroblasts in comparison to control cells (Supplementary Fig. 3a) . Levels of soluble TfR1, generated by cleavage of surface-bound TfR1, were elevated in patient sera (Supplementary Table 2 ), consistent with increased TfR1 expression on the cell surface. We examined TfR1 endocytosis in EpsteinBarr virus (EBV)-transformed B cells and activated T cells, both of which highly express TfR1 on the cell surface. Cross-linking of TfR1 dramatically decreased its cell surface expression on control but not patient-derived cells, demonstrating that the p.Tyr20His substitution impairs TfR1 internalization ( Fig. 2f and Supplementary Fig. 3b) . Furthermore, transduction of cells to express wild-type TfR1 but not Tyr20His TfR1 or GAPDH corrected defective transferrin uptake by patient-derived fibroblasts (Fig. 2g,h) . HSCT corrected TfR1 expression on patient T and B cells and fully corrected in vitro T and B cell function ( Supplementary Fig. 4 ).
TfR1-mediated iron uptake is essential for lymphocyte development and proliferation 8, 9 . Lymphocytes can also internalize iron through pathways involving non-transferrin-bound iron 10, 11 . Addition of iron citrate, which supersaturates transferrin so that excess free iron is internalized independently of TfR1, corrected the proliferation, IgE secretion and Iµ-Cε transcript expression of patient-derived lymphocytes (Fig. 3) . These findings demonstrate that insufficient iron uptake is the cause of the defective T and B cell activation underlying the CID in these families. Moreover, the nature of this CID phenotype indicates that pathways involving non-transferrin-bound iron cannot compensate for impaired TfR1 internalization in vivo, thus suggesting an essential role for TfR1 in host immunity.
To obtain further support for the pathogenicity of the p.Tyr20His substitution, we generated Tfrc Y20H/Y20H knock-in mice (Supplementary Fig. 5a,b) . In contrast to Tfrc −/− null mice 12 , Tfrc Y20H/Y20H mutant mice were viable, indicating that the mutation results in a hypomorphic allele. Tfrc Y20H/Y20H mice had significantly decreased serum IgG levels, hemoglobin levels and MCV in comparison to controls but normal percentages of splenic T and B cells, naive and memory T cells, NK cells and invariant NK T (iNKT) cells (Supplementary Table 5 ). However, Tfrc Y20H/Y20H T cells proliferated poorly in response to antibody against CD3 and treatment with PMA plus ionomycin, with proliferation significantly improved by the addition of iron citrate (Fig. 4a,b) . Tfrc Y20H/Y20H B cells proliferated poorly in response to stimulation with an antibody against CD40 and IL-4 and secreted minimal IgG1 and IgE in response to stimulation with lipopolysaccharide (LPS) and IL-4 (Fig. 4c) . TfR1 cell surface expression on mutant T and B cells was significantly increased, reflecting impaired internalization (Fig. 4d,e) .
The stringent requirement of mouse TfR1 for hemoglobin synthesis in erythroblasts and erythrocyte development accounts for the embryonic lethality observed in Tfrc −/− mice 12 . Therefore, the mild anemia in patients was unexpected. Cell surface expression of TfR1 on glycophorin A + (CD235a + ) erythroid precursor cells (EPCs) from bone marrow was increased by only 2-to 2.5-fold in patients as compared to controls ( Fig. 5a and Supplementary Fig. 6a,b) . Notably, the amount of TfR1 internalized by Tfrc Y20H/Y20H EPCs was similar to that for wild-type EPCs (Fig. 5b) 14 , and Steap3 −/− mice exhibit increased cell surface expression of TfR1 on erythroblasts and reticulocytes 16, 17 , suggesting that STEAP3 is important for optimal TfR1 internalization in erythroid cells. STEAP3 mRNA was highly expressed in normal human EPCs, whereas all four STEAP genes were poorly expressed in normal human fibroblasts, T cells and B cells (Fig. 5c) . Wild-type TfR1 and STEAP3 coimmunoprecipitated from lysates of cotransfected HEK293T cells, and both wild-type STEAP3 and the internalization-defective Tyr288His STEAP3 mutant associated with the Tyr20His TfR1 mutant (Fig. 5d,e) . Transfection to express wild-type STEAP3 but not Tyr288His mutant STEAP3 partially rescued defective transferrin uptake in patient-derived fibroblasts (Fig. 5f ). These findings suggest that, through interaction with TfR1, STEAP3 facilitates TfR1 endocytosis in EPCs, and this mechanism may protect patients with this CID from severe anemia. Heretofore, the role of TfR1 in host defense had not been established, and TFRC mutations had not been implicated in human disease. We describe a new CID caused by a homozygous mutation in TFRC that hinders TfR1-mediated iron internalization, resulting in defective T and B cell proliferation as well as impaired class-switching, which is necessary for antibody production. To our knowledge, this is the first human mutation implicating impaired iron transport in the pathogenesis of an immunodeficiency. We demonstrate that insufficient iron internalization constitutes the mechanism underlying this CID through in vitro correction of the lymphocyte defects in patients with iron citrate, which is internalized independently of TfR1. Furthermore, the relative importance of transferrin-dependent and non-transferrinbound iron to host immunity was previously unknown. Both the patients and Tfrc Y20H/Y20H mouse model demonstrate the essential role of iron internalized via TfR1 in immune function. Our data also suggest a new pathway for TfR1 endocytosis mediated by its interacting partner STEAP3, which may account for the mild effect of the mutation on erythropoiesis. Of clinical relevance, we have taken advantage of elevated TfR1 cell surface expression on lymphocytes to diagnose two patients at birth, thereby facilitating early cure by HSCT.
METHoDS
Methods and any associated references are available in the online version of the paper. 
oNLINE METHoDS
Study participants. We enrolled 34 members of a consanguineous Kuwaiti family (family A) and four members of a consanguineous family from western Saudi Arabia (family B) in the study. Genomic DNA was prepared from saliva, whole-blood samples or skin fibroblast cells. Informed consent was provided by adult donors or by the children's parents or guardian on forms approved by local ethics committees and by the Institutional Review Board at Boston Children's Hospital. DNA samples from 479 healthy donors of Middle Eastern ancestry and 252 subjects of European ancestry were used as controls. Protocols used in the human studies have been approved by the Committee on Clinical Investigations at Boston Children's Hospital.
Genetic analysis. Genomic DNA from 32 subjects (five affected and 27 unaffected) from family A and the proband from family B was genotyped at 909,622 SNPs on the Genome-Wide Human SNP 6.0 Array (Affymetrix). Genotype calling for linkage analysis in family A was performed using Birdseed v2 with a stringent confidence threshold of 0.02. To enrich for the highest performing and most informative SNPs, we then filtered the panel to include only 145,751 SNPs with an across-sample SNP Call Rate of 1.00, a Hardy-Weinberg equilibrium P value ≥1 × 10 −3 and a minor allele frequency >0.
Because of the high sample numbers and multiple consanguinity loops, the full family A pedigree was much larger than could be analyzed by any program that computes an exact logarithm of the odds ratio (LOD) score. Genome-wide linkage scans were therefore conducted with Merlin v1.1.2 (ref. 18 ) using a series of overlapping subfamilies. A focused linkage analysis of 127 SNPs on chromosome 3q28-ter and using all available subjects was conducted with SimWalk2 v2.91, which can analyze pedigrees of arbitrary size but computes an approximate rather than exact LOD score 19 .
PCR and Sanger DNA sequencing were performed according to standard protocols. Copy number analysis was performed in Genotyping Console software (Affymetrix). The mutation was genotyped in DNA samples from unrelated control subjects using a Custom TaqMan SNP Genotyping Assay (Applied Biosystems) on the 7900HT Sequence Detection System (Applied Biosystems). Quantitative RT-PCR of positional candidate genes was performed using TaqMan Gene Expression Assays (Applied Biosystems) on cDNA synthesized with High-Capacity RNA-to-cDNA Master Mix (Applied Biosystems), on the BioMark 48.48 Dynamic Array platform (Fluidigm), and analyzed using qbase PLUS v1.5 (Biogazelle).
Whole-genome sequencing and preliminary analysis (initial mappings of reads, local de novo assembly, and variant calling and annotation) were performed commercially by Complete Genomics 20 . We filtered variants for those that were homozygous in two affected subjects, heterozygous in an obligate carrier parent and absent from dbSNP v131 and that altered the amino acid sequence of an encoded protein or were in a consensus splice acceptor or splice donor site within 2 bp of an exon. The disease-causing variant has been submitted to ClinVar.
Cell preparation. Human PBMCs were isolated from heparinized blood obtained from patients and unaffected donors using Ficoll-Hypaque (GE Healthcare). Cells were suspended in RPMI-1640 containing 10% heatinactivated FCS (HyClone), 2 mM l-glutamine, 50 µg/ml streptomycin and 100 U/ml penicillin (medium). EBV-transformed cell lines were established as previously described 21 . Fibroblast cell lines were established from skin biopsies following standard procedures and were used after at least four or five passages. All cell lines were prepared using mycoplasma-free reagents. T and B cell populations were purified from PBMCs by negative magnetic separation (Miltenyi Biotec). Glycophorin A + red blood cell precursors and CD33 + myeloid cell progenitors were isolated from the bone marrow by positive magnetic sorting (Miltenyi Biotec).
Cell cultures. PBMCs (1 × 10 6 and 1.5 × 10 6 cells/ml for proliferation and immunoglobulin production, respectively) were cultured with medium, PHA (1 µg/ml; Sigma), antibody against CD3 (100 ng/ml; OKT3, eBioscience), PMA (20 nM; Sigma) plus ionomycin (0.5 µM; Sigma), and antibody against CD40 (5 µg/ml; 626.1) plus recombinant IL-4 (5 ng/ml; R&D Systems) for 4 d and with tetanus toxoid (National Institute for Biological Standards and Control) for 6 d. Ferric ammonium citrate (0.5 µg/ml; Sigma) was added where indicated.
Proliferation was assayed by measuring the incorporation of [ 3 H]thymidine that was added for the last 16 h of culture. The proliferative index (PI) was calculated as follows: PI = log(FI nd /MFI all )/log(2), where FI nd represents the peak fluorescence intensity of the viable non-divided cells and MFI all represents the median fluorescence intensity of all viable T cells. The production of IgE and IgG was measured in culture supernatants at 14 d by ELISA as described 22 . Upregulation by PMA and ionomycin of CD25, CD69 and CD40 ligand and upregulation by CD40 and IL-4 of CD23 and CD86 expression were analyzed by flow cytometry after 24 and 48 h, respectively. IL-2 in culture supernatants was measured after 48 h with ELISA kits from eBioscience.
Flow cytometry. Anti-human monoclonal antibodies to the following molecules and the appropriate isotype controls were used for staining: CD3 (HIT3a), CD19 (HIB19), CD27 (M-T271), CD23 (M-L233), CD86 (2331, FUN-1), TfR1 (M-A712), CD235a (GA-R2, HIR2), CD41a (HIP8) and CD42b (HIP1) from BD Biosciences; CD25 (BC96) and CD69 (FN50) from eBioscience; and CD40 ligand (40804) from R&D Systems. Standard flow cytometry methods were used for staining of cell surface proteins. Data collected with a FACSCalibur or an LSRFortessa cell analyzer (BD Biosciences) were analyzed with FlowJo software (TreeStar).
RT-PCR and quantitative RT-PCR. RNA was extracted from freshly isolated or cultured cells using TRIzol (Invitrogen) and was reverse transcribed by Superscript II (Invitrogen) according to the manufacturer's instructions using gene-specific PCR primers (Supplementary Table 6 ). Quantitative RT-PCR for TFRC and STEAP mRNA expression was performed using primers and an ABI Prism 7300 Sequence Detection System from Applied Biosystems. Relative RNA expression normalized to GAPDH mRNA abundance was calculated by the relative standard curve method as outlined in the manufacturer's technical bulletin (Applied Biosystems).
Immunoblot analysis. Cell lysates from PBMCs were separated by SDS-PAGE and transferred to nitrocellulose membranes. Specific proteins were detected using anti-human TfR1 monoclonal antibody (H68.4, Invitrogen), and blots were reprobed with monoclonal antibody to actin (Chemicon) as a loading control.
TfR1 internalization. EBV-transformed B cells from patients and controls
were washed with cold PBS and incubated with mouse anti-human TfR1 antibody (10 µg/ml; M-A712, BD Biosciences) or with mouse IgG2a isotype control for 30 min on ice. Cells were then washed with cold PBS and resuspended in cold PBS, and an aliquot was stained using FITC-conjugated rat anti-mouse IgG2a (RMG2a-62, BioLegend) to measure the baseline for TfR1 expression. The rest of the cells were placed at 37 °C for 15 and 30 min. Internalization was stopped by incubating the cells on ice and washing with cold PBS followed by staining and flow cytometry analysis 23 . The percentage of TfR1 internalized was calculated as follows: (MFI at 0 min − MFI at specified time point) × 100/MFI at 0 min.
Transferrin uptake assays. Patient and control fibroblasts were cultured on 12-mm coverslips in DMEM containing 15% FCS. Cells were washed with PBS and incubated at 37 °C overnight in serum-free DMEM. Transferrin conjugated to Alexa Fluor 568 (25 µg/ml; Invitrogen) was added to transferrinstarved cells for 30 min at 37 °C. Following incubation, cells were rinsed with ice-cold PBS and incubated in ice-cold acid wash buffer (0.025 M citric acid, 0.025 M sodium citrate, 0.15 M sucrose and 200 µM deferoxamine mesylate; all from Sigma) for exactly 3 min. This was followed by extensive rinses with serum-free medium and PBS. Cells were fixed in 4% paraformaldehyde in PBS, rinsed with PBS and mounted on coverslips using mounting medium (Prolong Gold with DAPI, Invitrogen). When dry, the coverslips were sealed and slides were imaged using a Nikon Eclipse 800 microscope. Mean red fluorescence intensity for 50 cells from 8-10 different fields was quantified using Nikon NS2 v3.2 imaging software.
Transduction of patient-derived fibroblasts with human TFRC. Wild-type human TFRC and GAPDH cDNA ORFs, cloned in the expression vector pLOC under the control of a CMV promoter, were purchased from Open Biosystems. The QuikChange site-directed mutagenesis kit (Stratagene) was used to generate npg the TFRC mutant encoding p.Tyr20His in the same vector. The vector expresses TurboGFP as a transfection marker independently through an internal ribosome entry site. The vector was packaged into lentiviral particles using the pseudotyped vesicular stomatitis virus lentiviral packaging system (Cell BioLabs). Patient and control fibroblasts were pretreated with polybrene (0.5 µg/ml; Sigma) and infected with lentivirus at a multiplicity of infection of 10. Eighteen hours after infection, the medium was replaced with fresh culture medium and the cells were monitored every 2 h for GFP expression. The transferrin uptake assay was performed when peak GFP expression was observed (after 24-28 h). Mean red fluorescence intensity for 50 GFP + cells from 8-10 different fields was quantified using Nikon NS2 v3.2 software.
Nucleofection of Steap3 into patient-derived fibroblasts. Sequences encoding FLAG-tagged mouse STEAP3 (six transmembrane epithelial antigen of prostate) and FLAG-tagged Tyr288His mutant STEAP3 were cloned in the expression vector pCMV-Tag3. One microgram of wild-type or mutant STEAP3-expressing plasmid was nucleofected into 0.75 × 10 6 fibroblasts with an Amaxa nucleofector (Lonza) using the program U-023 (high efficiency for normal human dermal fibroblasts) and plated on six-well clusters. After 24 h, cells were trypsinized and plated onto 12-mm coverslips. The transferrin uptake assay was performed after 24 h as described above, and the fixed cells were permeabilized with 0.2% saponin in PBS. After blocking with 4% BSA in PBS, the cells were incubated with mouse monoclonal antibody to FLAG (M2, Sigma), rinsed with Tris-buffered saline (TBS) and incubated with goat antimouse antibody conjugated to Alexa Fluor 488 (Invitrogen). After incubation, coverslips were rinsed with TBS and mounted and sealed as described above. Mean red fluorescence intensity for 25 FLAG + cells from 6-8 different fields was quantified using Nikon NS2 v3.2 software.
Transient transfections and coimmunoprecipitation. HEK293T cells (American Type Culture Collection) were cotransfected using Lipofectamine LTX (Invitrogen) with plasmids encoding Myc-DDK-tagged wild-type human TfR1 (Origene) or Tyr20His mutant TfR1 (prepared using the QuikChange site-directed mutagenesis kit from Stratagene) with either FLAG-tagged wildtype mouse STEAP3, FLAG-tagged Tyr288His mutant STEAP3 or FLAGtagged PYK2. After 19-24 h, cells were lysed with buffer containing 1% BRIJ 35 (Sigma). Immunoprecipitation was performed using monoclonal antibody to c-Myc (9E10, Millipore), followed by incubation with agarose protein G plus beads (Calbiochem). The complexes were separated by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted with antibody against c-Myc (9E10, Millipore) and FLAG (M2, Sigma).
Mouse studies. All experimental procedures performed on mice were approved by the Animal Care and Use Committee of Boston Children's Hospital. All experiments used 7-to 12-week-old, sex-matched Tfrc Y20H/Y20H mice and their wild-type littermates.
Generation of Tfrc Y20H/Y20H knock-in mice. A gene-targeting construct was generated to introduce the mutation encoding p.Tyr20His into exon 3 of mouse Tfrc. DNA fragments 3.5 kb and 3.3 kb in length were PCR amplified from the Tfrc gene in C57BL/6 genomic DNA and cloned into a gene-targeting vector upstream and downstream, respectively, of a neomycin resistance gene under the control of the PGK1 (phosphoglycerate kinase 1) promoter, used as a positive selectable marker. A gene fragment encoding diphtheria toxin A, located outside the homology arms, was used as a negative selectable marker. The c.58T>C mutation was introduced into the construct by site-directed mutagenesis, and the mutant clone was sequenced to ensure the absence of off-target PCR-induced mutations. The construct was then linearized and electroporated into C57BL/6N embryonic stem (ES) cells, which were selected for neomycin resistance using standard techniques 24 . ES cell clones that had successful integration of the targeting construct, as determined by Southern blot and PCR, were injected into C57BL/6 blastocysts, which were implanted into foster mothers. Offspring were genotyped by PCR and Sanger sequencing. Chimeric mice were backcrossed to generate germline Tfrc Y20H/+ heterozygous mice, which were then intercrossed to produce Tfrc Y20H/Y20H homozygousmutant mice. All mice were kept in a pathogen-free environment. Retro-orbital bleeds were performed to obtain peripheral blood for quantification of mouse hematological parameters (Hemavet 950FS) and serum immunoglobulins, which were quantified using standard ELISA techniques.
Mouse cell cultures and reagents. Anti-mouse monoclonal antibodies to the following molecules and the appropriate isotype controls were used for flow cytometry: CD4 (GK1.4), CD8 (53-6.7) and CD62L (MEL-14) from BioLegend and CD44 (IM7), CD25 (PC61.5), FOXP3 (FJK-16S), NK1.1 (PK136), CD49b (DX5) and Ter119 (TER-119) from eBioscience. Mouse CD1d (α-GalCer analog) was from the NIH Tetramer Facility-Emory University Vaccine Center. Mouse splenic T and B cells were purified by negative selection (Pan-T Cell Isolation Kit II and CD43 Kit, respectively, Miltenyi Biotec). Purified mouse T cells were labeled with CellTrace Violet (Invitrogen) according to the manufacturer's protocol and stimulated with plate-bound monoclonal antibody against CD3ε (5 µg/ml; 145-2C1), soluble monoclonal antibody against CD28 (2 µg/ml; 37.51) (both from eBioscience), recombinant mouse IL-2 (40 ng/ml; PeproTech), and PMA plus ionomycin for 96 h before FACS analysis. T cell proliferation was measured using the proliferative index (PI), calculated as described previously.
Purified B cells were stimulated with recombinant mouse IL-4 (50 ng/ml; R&D Systems) plus either antibody to mouse CD40 (1 µg/ml; HM40-3, Pharmingen) or LPS (10 µg/ml; Sigma). Proliferation was assayed at day 4 by measuring the incorporation of [ 3 H]thymidine, which was added for the last 16-20 h of culture. On day 7, supernatants were collected and assayed for IgE and IgG1 by ELISA. Standard flow cytometry methods were used for staining of cell surface proteins, and data were collected and analyzed as described for human cell staining. Fluorochrome-labeled monoclonal antibodies to the following mouse molecules and the appropriate controls were used for staining: TfR1 (R17217) from eBioscience and CD3 (17A2) and B220 (RA3-6B2) from BioLegend. For TfR1 internalization, resting mutant T cells and purified wild-type or mutant T cells stimulated with PMA and ionomycin for 16-18 h or bone marrow isolated from mouse femurs was used, following the same procedure performed on human EBV-transformed B cells. Erythroid precursors were identified using fluorochrome-labeled monoclonal antibodies to CD44 (IM7) and Ter119 (Ter-119) from eBioscience. Purified rat anti-mouse TfR1 (R17217) was used for cross-linking and phycoerythrin-conjugated goat anti-rat IgG was used for secondary detection of surface TfR1 expression. The percentage of TfR1 internalized was calculated as described previously. Internalized TfR1 in mouse erythroblasts was calculated as follows: MFI at 0 min − MFI after 30 min of TfR1 cross-linking.
Statistical analysis. Student's t test was used to compare groups with equal variances, and two-way ANOVA was used for comparing more than two groups. For mouse experiments, the sample size was determined using a conservative estimate of a 50% decrease in lymphocyte proliferation, immunoglobulin secretion, TfR1 expression and TfR1 internalization in Tfrc Y20H/Y20H cells in comparison to controls, with a standard deviation of 10%. To detect this difference with 95% power, we would need at least two mice of each genotype for each experiment. All experiments were performed a minimum of two times unless otherwise indicated.
